natgillin/translations-raw huggingface dataset:
What measures are being taken to ensure the safe and effective use of Prasugrel Mylan?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Prasugrel Mylan?
The use of Prasugrel Mylan is not recommended in patients over 75 years of age, unless the doctor has carefully considered its benefits and risks, and regards treatment with Prasugrel Mylan as necessary.
Uporaba zdravila Prasugrel Mylan ni priporočena pri bolnikih, starejših od 75 let, razen če zdravnik skrbno prouči njegove koristi in tveganja in oceni, da je zdravljenje z zdravilom Prasugrel Mylan potrebno.
Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Efient, and do not need to be repeated for Prasugrel Mylan.
Študije o koristih in tveganjih učinkovine pri odobrenem načinu uporabe so že bile izvedene z referenčnim zdravilom Efient, zato jih ni treba ponoviti za zdravilo Prasugrel Mylan.
This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent a heart attack or a stroke.
To preprečuje, da bi trombociti postali „lepljivi“, kar zmanjša tveganje za nastanek krvnega strdka in prispeva k preprečevanju srčnega infarkta ali kapi.
Prasugrel Mylan is taken together with aspirin to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) in patients with acute coronary syndrome who are undergoing percutaneous coronary intervention.
Zdravilo Prasugrel Mylan se jemlje sočasno z acetilsalicilno kislino (npr. aspirinom) za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročijo krvni strdki in zatrditev arterij) pri bolnikih z akutnim koronarnim sindromom, ki so imeli perkutano koronarno intervencijo.
It is recommended that treatment with Prasugrel Mylan and aspirin continue for up to a year.
Priporoča se, da se zdravljenje z zdravilom Prasugrel Mylan in acetilsalicilno kislino nadaljuje do enega leta.
In this case, the patient should take 5 mg daily following a 60-mg starting dose.
V tem primeru mora bolnik po začetnem 60-miligramskem odmerku jemati 5-miligramski dnevni odmerek.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Prasugrel Mylan have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Prasugrel Mylan upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Because Prasugrel Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Prasugrel Mylan generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The European Medicines Agency concluded that, in accordance with EU requirements, Prasugrel Mylan has been shown to have comparable quality and to be bioequivalent to Efient.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Prasugrel Mylan primerljivo raven kakovosti in je bioekvivalentno referenčnemu zdravilu Efient.
Acute coronary syndrome is a group of conditions in which blood supply in the vessels supplying the heart is interrupted so heart tissue cannot work properly or dies.
Akutni koronarni sindrom je skupina obolenj, pri katerih je dotok krvi v žilah, ki oskrbujejo srce, prekinjen, zaradi česar srčno tkivo ne more pravilno delovati ali odmre.
Prasugrel Mylan is available as tablets (5 and 10 mg) and can only be obtained with a prescription.
Zdravilo Prasugrel Mylan je na voljo v obliki tablet (5 in 10 mg), njegovo predpisovanje in izdaja pa je le na recept.
Why is Prasugrel Mylan authorised in the EU?
Zakaj je bilo zdravilo Prasugrel Mylan odobreno v EU?
Prasugrel Mylan treatment starts with one 60-mg dose.
Zdravljenje z zdravilom Prasugrel Mylan se začne z enim 60-miligramskim odmerkom.
The company that markets Prasugrel Mylan will make sure that educational materials are available for doctors who will treat patients with the medicine.
Podjetje, ki trži zdravilo Prasugrel Mylan, bo poskrbelo, da bo zdravnikom, ki bodo bolnike zdravili s tem zdravilom, na voljo izobraževalno gradivo.
As for every medicine, the company provided studies on the quality of Prasugrel Mylan.
Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Prasugrel Mylan.
For more information about using Prasugrel Mylan, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Prasugrel Mylan glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
This means that Prasugrel Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Efient.
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Efient.
This is then followed by 10 mg taken once a day, except in patients weighing less than 60 kg, who should take 5 mg once a day.
Temu sledi 10-miligramski odmerek enkrat na dan, razen pri bolnikih, ki tehtajo manj kot 60 kg, ki morajo vzeti 5 mg enkrat na dan. Bolniki, ki jemljejo zdravilo Prasugrel Mylan, morajo prav tako jemati acetilsalicilno kislino, in sicer v odmerku, ki jim ga je predpisal zdravnik.
What is Prasugrel Mylan and what is it used for?
Kaj je zdravilo Prasugrel Mylan in za kaj se uporablja?
As for all medicines, data on the use of Prasugrel Mylan are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Prasugrel Mylan stalno spremljajo.
Percutaneous coronary intervention is a procedure used to unblock the blood vessels supplying the heart.
Perkutana koronarna intervencija je postopek za odpravo zapor krvnih žil, ki oskrbujejo srce.
Side effects reported with Prasugrel Mylan are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Prasugrel Mylan, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
An overview of Prasugrel Mylan and why it is authorised in the EU
Pregled zdravila Prasugrel Mylan in zakaj je odobreno v EU
What are the benefits and risks of Prasugrel Mylan?
Kakšne so koristi in tveganja zdravila Prasugrel Mylan?
Prasugrel Mylan contains the active substance prasugrel and is a ‘generic medicine'.
Zdravilo Prasugrel Mylan vsebuje učinkovino prasugrel in je „generično zdravilo“.
Therefore, the Agency's view was that, as for Efient, the benefit of Prasugrel Mylan outweighs the identified risk and it can be authorised for use in the EU.
Zato je agencija menila, da koristi zdravila Prasugrel Mylan, enako kot pri zdravilu Efient, odtehtajo znana tveganja in se zdravilo lahko odobri v EU.
Blood clots are caused by special cells in the blood, the platelets, sticking together (aggregating).
Krvne strdke povzroča zlepljanje (agregacija) posebnih celic v krvi, imenovanih trombociti.
Other information about Prasugrel Mylan
Druge informacije o zdravilu Prasugrel Mylan
Prasugrel stops the platelets aggregating by blocking a substance called ADP from binding to a receptor (target) on their surface.
Prasugrel z zaviranjem vezave snovi, imenovane ADP (adenozin difosfat), na receptor (prijemališče) na površini trombocitov prepreči njihovo agregacijo.
How is Prasugrel Mylan used?
Kako se zdravilo Prasugrel Mylan uporablja?
How does Prasugrel Mylan work?
Kako zdravilo Prasugrel Mylan deluje?
The active substance in Prasugrel Mylan, prasugrel, is an inhibitor of platelet aggregation.
Učinkovina v zdravilu Prasugrel Mylan, prasugrel, je zaviralec agregacije trombocitov.
How has Prasugrel Mylan been studied?
Kako je bilo zdravilo Prasugrel Mylan raziskano?
Pack size
Subkutana uporaba e
Article 29(4) of Directive 2001/83/EC, as amended.
Člen 29(4) Direktive 2001/83/ES, kakor je bila spremenjena.
The Reference Member State was Hungary and the Concerned Member States were Czech Republic, Estonia, Hungary, Lithuania, Latvia, Poland, Romania and Slovak Republic.
Referenčna država članica je bila Madžarska, zadevne države članice pa Češka republika, Estonija, Madžarska, Litva, Latvija, Poljska, Romunija in Slovaška.
The Mutual Recognition Procedure started on 3 August 2007.
Postopek medsebojnega priznavanja se je začel dne 3. avgusta 2007.
The final opinion was converted into a Decision by the European Commission on 12 November 2008.
Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 12. novembra 2008.
The Czech Republic and Latvia referred the reasons for disagreement to the EMEA on 1 February 2008.
Češka republika in Latvija sta svoje razloge za nesoglasje agenciji EMEA podali dne 1. februarja 2008.
The arbitration procedure started on 21 February 2008 with the adoption of a list of questions.
Arbitražni postopek se je začel 21. februarja 2008 s sprejetjem seznama vprašanj.
Concerns related to the formal proof of bioequivalence and the lack of a wide therapeutic experience which were considered a potential serious risk to public health.
Zadržki so se nanašali na uradni dokaz biološke enakovrednosti in pomanjkanje obsežnih terapevtskih izkušenj, kar se je štelo kot možno resno tveganje za javno zdravje.
These Member States were not able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State.
Te države članice niso mogle doseči soglasja glede medsebojnega priznavanja dovoljenja za promet z zdravilom, ki ga je odobrila referenčna država članica.
The Rapporteur was Dr Ondřej Slanař (CZ) and Co-Rapporteur(s) was Prof János Borvendég (HU).
Poročevalec je bil dr. Ondřej Slanař (CZ), soporočevalec pa prof. János Borvendég (HU).
The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III.
Seznam zadevnih imen izdelkov je naveden v Dodatku I. Znanstveni zaključki so navedeni v Dodatku II, povzetek glavnih značilnosti zdravila pa v Dodatku III.
The Summary of Product Characteristics, Labelling and Package Leaflet of the Reference Member State should be amended.
Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo referenčne države članice je treba spremeniti.
During their July 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Lisonorm, that the objections raised by Czech Republic and Latvia should not prevent the granting of a Marketing Authorisation.
CHMP je na zasedanju julija 2008 ob upoštevanju vseh predloženih podatkov in znanstvene razprave v okviru Odbora menil, da je razmerje med koristnimi učinki in tveganji za zdravilom Lisonorm ugodno, da zadržki, ki sta jih podali Češka republika in Latvija, ne bi smeli preprečiti odobritve dovoljenja za promet z zdravilom.
Lisonorm tablet contains 5mg amlodipine/ 10mg lisinopril and is an anti-hypertensive indicated in patients with blood pressure adequately controlled with lisinopril and amlodipine given concurrently at the same dose level.
Tableta Lisonorm vsebuje 5 mg amlodipina /10 mg lizinoprila in je antihipertenziv, indiciran za bolnike, pri katerih je krvni tlak primerno nadzorovan z lizinoprilom in amlodipinom, ki se bolniku dajeta sočasno pri enakem odmerku zdravila.
A positive opinion was adopted by consensus on 24 July 2008.
Odbor je dne 24. julija 2008 na podlagi soglasja izdal pozitivno mnenje.
The Marketing Authorisation Holder provided written explanations on 2 June 2008.
Imetnik dovoljenja za promet z zdravilom je predložil pisna pojasnila 2. junija 2008.
Gedeon Richter Plc obtained a national marketing authorisation for Lisonorm which was authorised in Bulgaria on 29 December 2006, before Bulgaria joined the European Union.
Družba Gedeon Richter Plc je prejela nacionalno dovoljenje za promet z zdravilom Lisonorm, ki je bilo odobreno v Bolgariji dne 29. decembra 2006, preden se je Bolgarija pridružila Evropski uniji.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR Lisonorm and associated names International Non-Proprietary Name (INN): lisinopril + amlodipine
ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 29(4)1 ZA ZDRAVILO Lisonorm in z njim povezana imena Mednarodno nelastniško ime (INN): lizinopril + amlodipin
Gedeon Richter Plc submitted a Marketing Authorisation Application (MAA) via mutual recognition procedure for Lisonorm on the basis of the marketing authorisation granted by Hungary on 30 April 2004.
Družba Gedeon Richter Plc je predložila vlogo za odobritev dovoljenja za promet s postopkom medsebojnega priznavanja za zdravilo Lisonorm, in sicer na podlagi dovoljenja za promet z zdravilom, ki ga je odobrila Madžarska dne 30. aprila 2004.
27 July 2010
27. julija 2010
The final opinion was converted into a Decision by the European Commission on 27 July 2010.
Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 27. julija 2010.
1 Article 34 of Directive 2001/82/EC
1 Člen 34 Direktive 2001/82/ES
The referral procedure started on 15 October 2008.
Napotitveni postopek se je začel 15. oktobra 2008.
Oral explanations were given on 10 February 2010.
Ustna pojasnila so bila podana dne 10. februarja 2010.
The target species are: pigs, chickens, turkeys and rabbits.
Ciljne vrste so: prašiči, piščanci, purani in zajci.
Opinion following an Article 34
Mnenje v zvezi z napotitvijo v skladu s členom 34
Written explanations were provided by the marketing authorisation holders on 20 April 2009 and 16 November 2009.
Pisna pojasnila so imetniki dovoljenja za promet z zdravilom predložil dne 20. aprila 2009 in 16. novembra 2009.
The rapporteur and co-rapporteur appointed were: Prof. Stane Srčič and Dr Karolina Törneke respectively.
Za poročevalca oziroma soporočevalko sta bila imenovana: prof. Stane Srčič in dr. Karolina Törneke.
Tiamulin is a semi-synthetic antibiotic belonging to the pleuromutilin group of antibiotics and it is used only in veterinary medicine.
Tiamulin je polsintezni antibiotik iz skupine antibiotikov pleuromutilinov in se uporablja le v veterinarski medicini.
referral for Tiamutin premix and associated names
za zdravilo Tiamutin premix in z njim povezana imena
Premixes containing tiamulin are marketed across the European Union under a variety of invented names and the authorised premix formulations are based on tiamulin hydrogen fumarate in a variety of concentrations: 0.8%, 2%, 10% and 80%.
Predmešanice s tiamulinom se po vsej Evropski uniji tržijo pod različnimi izmišljenimi imeni, odobrene formulacije predmešanice pa temeljijo na tiamulinijevem hidrogenfumaratu v različnih koncentracijah: 0,8 %, 2 %, 10 % in 80 %.
Due to differences among the nationally authorised summaries of product characteristics for Tiamutin premix and associated names across the European Union, especially as regards indications for use, amount to be administered and administration route and withdrawal periods, on 18 September 2008 Ireland and Belgium referred the matter to the European Medicines Agency under Article 34 of Directive 2001/82/EC.
Zaradi razlik med nacionalno odobrenimi glavnimi povzetki značilnosti za zdravilo Tiamutin premix in z njim povezana imena v Evropski uniji, še zlasti glede navodila za uporabo, odmerjene količine in poti uporabe ter karence, sta Irska in Belgija dne 18. septembra 2008 v skladu s členom 34 Direktive 2001/82/ES zadevo napotila na Evropsko agencijo za zdravila.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended summary of product characteristics and labelling in Annex III.
Seznam zadevnih imen zdravil je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, skupaj s spremenjenim povzetkom glavnih značilnosti zdravila in označevanjem v Dodatku III.
Tiamulin is used for the treatment and prevention of gastrointestinal and respiratory infections caused by different bacterial pathogens in pigs, poultry and rabbits.
Uporablja se za zdravljenje in preprečevanje gastrointestinalnih okužb in okužb dihal, ki jih pri prašičih, perutnini in zajcih povzročajo različni bakterijski povzročitelji.
Based on the rapporteurs' assessment of the currently available data, the CVMP adopted, on 10 March 2010, an opinion recommending the amendment of the marketing authorisations in terms of the summary of the product characteristics and labelling in order to harmonise the indications for use, amount to be administered and administration route and withdrawal periods.
Na podlagi poročevalčeve ocene trenutno razpoložljivih podatkov je CVMP dne 10. marca 2010 sprejel mnenje, v katerem priporoča spremembo dovoljenj za promet z zdravilom glede povzetka glavnih značilnost zdravila in označevanja, da bi se uskladili indikacije za uporabo, odmerjene količine, pot uporabe in karence.
This overview was last updated in 12-2018.
Pregled je bil nazadnje posodobljen 12-2018.
Further information on Yervoy can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Yervoy.
Nadaljnje informacije za zdravilo Yervoy so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Yervoy.
What measures are being taken to ensure the safe and effective use of Yervoy?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Yervoy?
The effects of Yervoy in adolescents are expected to be similar to those in adults.
Pričakovati je, da bodo učinki zdravila Yervoy pri mladostnikih podobni kot pri odraslih.
Patients will also receive from their doctor an alert card summarising key safety information on the medicine.
Bolniki bodo od zdravnika prejeli tudi opozorilno kartico, na kateri so povzete ključne varnostne informacije o zdravilu.
Yervoy received a marketing authorisation valid throughout the EU on 13 July 2011.
Za zdravilo Yervoy je bilo 13. julija 2011 izdano dovoljenje za promet, veljavno po vsej EU.
The Agency decided that Yervoy's benefits are greater than its risks and it can be authorised for use in the EU.
Agencija je zaključila, da so koristi zdravila Yervoy večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Advanced melanoma
Napredovali melanom
What benefits of Yervoy have been shown in studies?
Kakšne koristi zdravila Yervoy so se pokazale v študijah?
Other information about Yervoy
Druge informacije o zdravilu Yervoy
Why is Yervoy authorised in the EU?
Zakaj je bilo zdravilo Yervoy odobreno v EU?
Therefore, all adolescents treated with Yervoy will be monitored closely.
Zato bodo vsi mladostniki, zdravljeni z zdravilom Yervoy, skrbno nadzorovani.
An overview of Yervoy and why it is authorised in the EU
Pregled zdravila Yervoy in zakaj je odobreno v EU
As for all medicines, data on the use of Yervoy are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Yervoy stalno spremljajo.
What are the risks associated with Yervoy?
Kakšna tveganja so povezana z zdravilom Yervoy?
Advanced renal cell carcinoma
Napredovali karcinom ledvičnih celic
In addition, 41.6% of patients (177 out of 423) responded to the treatment with the combination compared with 26.5% (112 out of 416) of those receiving sunitinib.
Poleg tega se je na zdravljenje s kombinacijo omenjenih zdravil odzvalo 41,6 % (177 od 423) bolnikov v primerjavi s 26,5 % (112 od 416) bolnikov, ki so prejemali sunitinib.
What is Yervoy and what is it used for?
Kaj je zdravilo Yervoy in za kaj se uporablja?
Several studies have shown that Yervoy is effective in prolonging the lives of patients with advanced melanoma.
Več študij je pokazalo, da je zdravilo Yervoy učinkovito pri podaljševanju življenja bolnikov z napredovalim melanomom.
Side effects reported with Yervoy are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Yervoy, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
For more information about using Yervoy, see the package leaflet or contact a doctor or pharmacist.
Za več informacij glede uporabe zdravila Yervoy glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
As it is not clear how much Yervoy contributes to the benefits when given in combination with nivolumab in patients with advanced renal cell carcinoma, the company must conduct a study to determine the precise contribution of Yervoy and if the risks associated with Yervoy can be further minimised.
Ker ni jasno, v kolikšni meri zdravilo Yervoy doprinese h koristim zdravljenja, kadar se uporablja v kombinaciji z nivolumabom pri bolnikih z napredovalim karcinomom ledvičnih celic, mora podjetje izvesti študijo za določitev natančnega doprinosa zdravila Yervoy in raziskati, ali je mogoče z njim povezana tveganja še dodatno zmanjšati.
In the treatment of melanoma, despite longer survival with a dose of 10 mg per kg, the Agency recommended using Yervoy at a dose of 3 mg per kg because the higher dose caused more side effects and worsened patients' quality of life after the start of treatment.
Pri zdravljenju melanoma je agencija kljub daljšemu preživetju pri odmerku 10 mg na kg telesne mase priporočila, naj se zdravilo Yervoy uporablja v odmerku 3 mg na kg telesne mase, saj je večji odmerek povzročil več neželenih učinkov in poslabšal kakovost življenja bolnikov po začetku zdravljenja.
Ipilimumab increases the number and the activity of a type of white blood cells called T cells which form part of the immune system and which can kill cancer cells.
Ipilimumab povečuje število in aktivnost vrste belih krvnih celic, imenovanih celice T, ki so del imunskega sistema in imajo sposobnost uničevanja rakavih celic.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yervoy have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Yervoy upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Because studies with Yervoy have included very few adolescents, the company has committed to collecting information on side effects, including any effects on growth and sexual maturation.
Ker so študije z zdravilom Yervoy vključevale zelo malo mladostnikov, se je podjetje zavezalo, da bo zbiralo informacije o neželenih učinkih, vključno z morebitnimi učinki na rast in spolno dozorevanje.
Because the medicine has been studied in very few adolescents, there is uncertainty about the medicine's side effects.
Ker so zdravilo proučevali pri zelo majhnem številu mladostnikov, obstaja negotovost glede njegovih neželenih učinkov.
Most will improve with appropriate treatment or on stopping Yervoy.
Večina učinkov izzveni z ustreznim zdravljenjem ali prekinitvijo uporabe zdravila Yervoy.
The company that markets Yervoy must ensure that all healthcare professionals expected to prescribe the medicine as well as patients are given a brochure with safety information on the medicine including the side effects resulting from excessive activity of the immune system.
Podjetje, ki trži zdravilo Yervoy, mora zagotoviti, da bodo vsi zdravstveni delavci, ki bodo predpisovali zdravilo, in vsi bolniki prejeli brošuro z informacijami o varnosti zdravila ter njegovih neželenih učinkih zaradi čezmernega delovanja imunskega sistema.
Yervoy is given by infusion (drip) into a vein over 90 minutes and the dose depends on the patient's body weight.
Zdravilo Yervoy se daje z 90-minutnim infundiranjem (kapalno infuzijo) v veno, pri čemer je odmerek odvisen od bolnikove telesne mase.